Population Pharmacokinetics and Exposure–Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Exposure–Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease

Published:2022-10 Issue:10 Volume:44 Page:1336-1355
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Adedokun Omoniyi J.^ORCID,Xu Zhenhua,Gasink Christopher,Kowalski Ken,Sandborn William J.,Feagan Brian

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference39 articles.

1. INN-Ustekinumab Prescribing Information,2022

2. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis;Zhu;J Clin Pharmacol,2009

3. Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease;Wang;Br J Clin Pharmacol,2022

4. European Medicines Agency. Assessment report: Stelara. 15 September 2016. Accessed April 19, 2022. https://www.ema.europa.eu/en/documents/variation-report/stelara-h-c-000958-x-0049-g-epar-assessment-report-extension_en.pdf.

5. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease;Adedokun;Gastroenterology,2018

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies;Journal of Pharmaceutical Sciences;2024-09

2. Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of Ustekinumab in pediatric patients with inflammatory bowel disease;European Journal of Pharmaceutical Sciences;2024-08

3. Utility of Cellular Measurements of Non-Specific Endocytosis to Assess the Target-Independent Clearance of Monoclonal Antibodies;Journal of Pharmaceutical Sciences;2024-07

4. The Future of Clinical Trials in Inflammatory Bowel Disease;Clinical Gastroenterology and Hepatology;2024-07

5. Utility of Cellular Measurements of Non-Specific Endocytosis to Assess the Target-Independent Clearance of Monoclonal Antibodies;2024-04-16